Medically reviewed by Drugs.com. Last updated on Aug 28, 2020.
(e DAR a vone)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Radicava: 30 mg/100 mL (100 mL) [contains sodium bisulfite]
Brand Names: U.S.
- Free Radical Scavenger
The mechanism by which edaravone slows the decline of physical function in patients with ALS is unknown. Edaravone is a free radical and peroxynitrite scavenger that prevents oxidative damage to cell membranes and may contribute to inhibiting the progression of ALS (Nagase 2016).
Metabolized to inactive sulfate and glucuronide conjugates; sulfate conjugate formed by sulfotransferases. Glucuronide conjugation involves UGT1A6, UGT1A9, UGT2B7, and UGT2B17 in the liver and kidney.
Urine (70% to 90% as glucuronide conjugate; 5% to 10% as sulfate conjugate; ≤1% unchanged)
Time to Peak
4.5 to 6 hours
92% (mainly albumin)
Use: Labeled Indications
Amyotrophic lateral sclerosis: Treatment of amyotrophic lateral sclerosis (ALS)
Hypersensitivity to edaravone or any component of the formulation
Amyotrophic lateral sclerosis (ALS): IV:
Initial cycle: 60 mg once daily for 14 days, followed by a 14-day drug-free period.
Subsequent cycles: 60 mg once daily for 10 days within a 14-day period, followed by a 14-day drug-free period.
Refer to adult dosing. Use with caution.
IV: For IV use only. Administer as two consecutive 30 mg infusion bags (60 mg total) over 60 minutes (infusion rate: ~1 mg/minute [3.33 mL/minute]). Do not mix edaravone with other medications. Do not use if the oxygen indicator has turned blue or purple before opening. Promptly discontinue with any signs or symptoms consistent with a hypersensitivity reaction.
Store at ≤25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Once overwrap package is opened, use within 24 hours.
There are no known significant interactions.
Central nervous system: Abnormal gait (13%)
Hematologic & oncologic: Bruise (15%)
1% to 10%:
Central nervous system: Headache (10%)
Dermatologic: Dermatitis (8%), eczema (7%), tinea (4%)
Endocrine & metabolic: Glycosuria (4%)
Respiratory: Dyspnea (≤6%), hypoxia (≤6%), respiratory failure (≤6%)
<1%, postmarketing, and/or case reports: Anaphylaxis, hypersensitivity reaction
Concerns related to adverse effects:
• Hypersensitivity: Hypersensitivity reactions (eg, redness, wheals, erythema multiforme) and anaphylaxis have been reported. If hypersensitivity occurs, discontinue treatment and monitor.
Dosage form specific issues:
• Sodium bisulfite: May contain sodium bisulfite; use caution in patients with asthma or a sulfite allergy.
Adverse events were observed in some animal reproduction studies.
What is this drug used for?
• It is used to treat amyotrophic lateral sclerosis (ALS).
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
• Skin irritation
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• Severe dizziness
• Passing out
• Shortness of breath
• Trouble walking
• Change in balance
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about edaravone
- Side Effects
- During Pregnancy
- Dosage Information
- En Español
- Drug class: miscellaneous central nervous system agents
Other brands: Radicava